Sugi Predict

Sugi Predict / Compounds / SCHEMBL2446490

SCHEMBL2446490

SCHEMBL2446490

Cc1ccc(S(=O)(=O)N2CCN(S(=O)(=O)c3ccc(C)cc3)CC(O)C2)cc1

nearest known ligand 0.87

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 3/20 0.66
▸ ALDH1A1 P00352 3/20 0.64
▸ HTT P42858 2/20 0.64
▸ POLB P06746 1/20 0.64
▸ TSHR P16473 1/20 0.63
▸ CYP2C19 P33261 1/20 0.63
▸ KMT2A Q03164 7/20 0.58
▸ MEN1 O00255 3/20 0.58
▸ GAA P10253 2/20 0.58
▸ LMNA P02545 2/20 0.57
▸ SMN1; SMN2 Q16637 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19011448 0.93 PKM (0.59) PKMALDH1A1HTTPOLBTSHR
SCHEMBL4516709 0.90 PKM (0.57) PKMALDH1A1HTTPOLBTSHR
SCHEMBL3235046 0.90 PKM (0.57) PKMALDH1A1HTTPOLBTSHR
SCHEMBL3235054 0.90 PKM (0.57) PKMALDH1A1HTTPOLBTSHR
SCHEMBL12169319 0.87 AKR1C3 (0.62) PKMALDH1A1HTTPOLBTSHR
SCHEMBL10361037 0.84 AKR1C3 (0.58) PKMALDH1A1HTTPOLBKMT2A
SCHEMBL8203532 0.83 PKM (0.88) PKMALDH1A1HTTPOLBTSHR
SCHEMBL565301 0.83 PKM (0.88) PKMALDH1A1HTTPOLBTSHR
SCHEMBL4537086 0.83 PKM (0.88) PKMALDH1A1HTTPOLBTSHR
SCHEMBL10724066 0.83 PKM (0.88) PKMALDH1A1HTTPOLBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023192989-A2 PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS AZKARRA THERAPEUTICS, INC. (US) 2023-10-05 — — WO disclosed
US-11420910-B2 Methods for low temperature fluorine-18 radiolabeling of biomolecules KATHOLIEKE UNIVERSITET LEUVEN (BE) 2022-08-23 — — US disclosed
EP-3212610-B1 METHODS FOR LOW TEMPERATURE FLUORINE-18 RADIOLABELING OF BIOMOLECULES UNIV LEUVEN KATH (BE) 2020-10-28 — — EP disclosed
US-20180273441-A1 METHODS FOR LOW TEMPERATURE FLUORINE-18 RADIOLABELING OF BIOMOLECULES KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2018-09-27 — — US disclosed
EP-2721019-B1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE AGIOS PHARMACEUTICALS INC (US) 2018-08-08 — — EP disclosed
US-9856279-B2 Therapeutically active compositions and their methods of use AGIOS PHARMACEUTICALS, INC. (US) 2018-01-02 — — US disclosed
US-9856279-B2 Therapeutically active compositions and their methods of use AGIOS PHARMACEUTICALS, INC. (US) 2018-01-02 — — US disclosed
EP-3212610-A2 METHODS FOR LOW TEMPERATURE FLUORINE-18 RADIOLABELING OF BIOMOLECULES Katholieke Universiteit Leuven (BE) 2017-09-06 — — EP disclosed
US-20160229876-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC 2016-08-11 — — US disclosed
US-20160229876-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC 2016-08-11 — — US disclosed
EP-1446401-A4 C-5 MODIFIED INDAZOLYLPYRROLOTRIAZINES BRISTOL MYERS SQUIBB CO (US) 2006-04-12 — — EP disclosed
US-20050209235-A1 C-5 Modified indazolylpyrrolotriazines MASTALERZ HAROLD 2005-09-22 — — US disclosed
US-6908916-B2 C-5 modified indazolylpyrrolotriazines BRISTOL MYERS SQUIBB COMPANY (US) 2005-06-21 — — US disclosed
US-6828316-B2 Antiallergens KOWA CO., LTD. (JP) 2004-12-07 — — US disclosed
EP-1446401-A2 C-5 MODIFIED INDAZOLYLPYRROLOTRIAZINES Bristol-Myers Squibb Company (US) 2004-08-18 — — EP disclosed
US-20030186983-A1 C-5 Modified indazolylpyrrolotriazines BRISTOL-MYERS SQUIBB COMPANY 2003-10-02 — — US disclosed
WO-2003042172-A2 C-5 MODIFIED INDAZOLYLPYRROLOTRIAZINES BRISTOL-MYERS SQUIBB COMPANY (US) 2003-05-22 — — WO disclosed
US-20020042414-A1 Diamide compound and medicine containing the same KOWA CO., LTD. (JP) 2002-04-11 — — US disclosed
US-6340682-B1 FOR THERAPY OF ALLERGIC IMMUNOLOGICAL DISEASE IS SELECTED FROM ASTHMA, ALLERGIC RHINITIS, INFLAMMATORY LARGE BOWEL DISEASE OR CONTACT DERMATITIS KOWA CO., LTD. (JP) 2002-01-22 — — US disclosed
EP-0926138-A1 DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME KOWA CO. LTD. (JP) 1999-06-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186983-A1 C-5 Modified indazolylpyrrolotriazines ERBB2, ERBB4, EGFR PKM 3605/4885ALDH1A1 2091/4885HTT 3603/4885
US-20020042414-A1 Diamide compound and medicine containing the same HRH4, HRH2, HRH1 PKM 3494/4885ALDH1A1 836/4885HTT 2457/4885
US-20180273441-A1 METHODS FOR LOW TEMPERATURE FLUORINE-18 RADIOLABELING OF BIOMOLECULES H1-3, H1-0, H1-2 PKM 3570/4885ALDH1A1 2544/4885HTT 3817/4885
US-20050209235-A1 C-5 Modified indazolylpyrrolotriazines ERBB2, ERBB4, EGFR PKM 3571/4885ALDH1A1 2381/4885HTT 3420/4885
US-20160229876-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE MCL1, TP53, MMP8 PKM 2389/4885ALDH1A1 1551/4885HTT 1632/4885
US-11420910-B2 Methods for low temperature fluorine-18 radiolabeling of biomolecules H1-3, H1-0, H1-2 PKM 3539/4885ALDH1A1 2510/4885HTT 3854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.